West Pharmaceutical Services (WST) Competitors

West Pharmaceutical Services logo
$336.09 +6.38 (+1.94%)
As of 03:58 PM Eastern

WST vs. CHE, EHC, COO, ALGN, and MMSI

Should you buy West Pharmaceutical Services stock or one of its competitors? MarketBeat compares West Pharmaceutical Services with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with West Pharmaceutical Services include Chemed (CHE), Encompass Health (EHC), Cooper Companies (COO), Align Technology (ALGN), and Merit Medical Systems (MMSI). These companies are all part of the "medical" sector.

How does West Pharmaceutical Services compare to Chemed?

West Pharmaceutical Services (NYSE:WST) and Chemed (NYSE:CHE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

In the previous week, West Pharmaceutical Services had 2 more articles in the media than Chemed. MarketBeat recorded 4 mentions for West Pharmaceutical Services and 2 mentions for Chemed. West Pharmaceutical Services' average media sentiment score of 0.97 beat Chemed's score of 0.95 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Chemed
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 3.3% of Chemed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

West Pharmaceutical Services has higher revenue and earnings than Chemed. Chemed is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B7.72$493.70M$7.4844.93
Chemed$2.53B2.33$265.24M$18.3524.21

West Pharmaceutical Services has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Chemed has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

West Pharmaceutical Services pays an annual dividend of $0.88 per share and has a dividend yield of 0.3%. Chemed pays an annual dividend of $2.40 per share and has a dividend yield of 0.5%. West Pharmaceutical Services pays out 11.8% of its earnings in the form of a dividend. Chemed pays out 13.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Chemed has increased its dividend for 16 consecutive years. Chemed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

West Pharmaceutical Services presently has a consensus price target of $340.09, suggesting a potential upside of 1.19%. Chemed has a consensus price target of $501.50, suggesting a potential upside of 12.90%. Given Chemed's higher possible upside, analysts plainly believe Chemed is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00
Chemed
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

West Pharmaceutical Services has a net margin of 16.85% compared to Chemed's net margin of 10.23%. Chemed's return on equity of 27.18% beat West Pharmaceutical Services' return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.85% 19.03% 14.06%
Chemed 10.23%27.18%17.38%

Summary

West Pharmaceutical Services beats Chemed on 12 of the 20 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Encompass Health?

West Pharmaceutical Services (NYSE:WST) and Encompass Health (NYSE:EHC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

In the previous week, Encompass Health had 2 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 6 mentions for Encompass Health and 4 mentions for West Pharmaceutical Services. Encompass Health's average media sentiment score of 1.63 beat West Pharmaceutical Services' score of 0.97 indicating that Encompass Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Encompass Health
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

West Pharmaceutical Services pays an annual dividend of $0.88 per share and has a dividend yield of 0.3%. Encompass Health pays an annual dividend of $0.76 per share and has a dividend yield of 0.8%. West Pharmaceutical Services pays out 11.8% of its earnings in the form of a dividend. Encompass Health pays out 12.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Encompass Health has increased its dividend for 2 consecutive years. Encompass Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 97.3% of Encompass Health shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 1.8% of Encompass Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Encompass Health has higher revenue and earnings than West Pharmaceutical Services. Encompass Health is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B7.72$493.70M$7.4844.93
Encompass Health$5.94B1.68$566.20M$5.9916.73

West Pharmaceutical Services has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Encompass Health has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

West Pharmaceutical Services has a net margin of 16.85% compared to Encompass Health's net margin of 10.04%. West Pharmaceutical Services' return on equity of 19.03% beat Encompass Health's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.85% 19.03% 14.06%
Encompass Health 10.04%18.28%8.27%

West Pharmaceutical Services currently has a consensus target price of $340.09, indicating a potential upside of 1.19%. Encompass Health has a consensus target price of $143.86, indicating a potential upside of 43.54%. Given Encompass Health's higher probable upside, analysts clearly believe Encompass Health is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00
Encompass Health
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

West Pharmaceutical Services beats Encompass Health on 10 of the 19 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Cooper Companies?

West Pharmaceutical Services (NYSE:WST) and Cooper Companies (NASDAQ:COO) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

West Pharmaceutical Services has higher earnings, but lower revenue than Cooper Companies. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B7.72$493.70M$7.4844.93
Cooper Companies$4.09B3.15$374.90M$1.1856.06

West Pharmaceutical Services has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Cooper Companies has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 24.4% of Cooper Companies shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 2.1% of Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cooper Companies had 8 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 12 mentions for Cooper Companies and 4 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 0.97 beat Cooper Companies' score of 0.62 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cooper Companies
5 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

West Pharmaceutical Services currently has a consensus target price of $340.09, indicating a potential upside of 1.19%. Cooper Companies has a consensus target price of $81.31, indicating a potential upside of 22.91%. Given Cooper Companies' higher probable upside, analysts plainly believe Cooper Companies is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00
Cooper Companies
3 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.38

West Pharmaceutical Services has a net margin of 16.85% compared to Cooper Companies' net margin of 5.57%. West Pharmaceutical Services' return on equity of 19.03% beat Cooper Companies' return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.85% 19.03% 14.06%
Cooper Companies 5.57%10.88%7.27%

Summary

West Pharmaceutical Services beats Cooper Companies on 12 of the 17 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Align Technology?

Align Technology (NASDAQ:ALGN) and West Pharmaceutical Services (NYSE:WST) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Align Technology presently has a consensus target price of $205.85, indicating a potential upside of 22.17%. West Pharmaceutical Services has a consensus target price of $340.09, indicating a potential upside of 1.19%. Given Align Technology's higher possible upside, research analysts clearly believe Align Technology is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Align Technology
0 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.71
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00

West Pharmaceutical Services has lower revenue, but higher earnings than Align Technology. Align Technology is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$4.03B2.99$410.35M$5.9628.27
West Pharmaceutical Services$3.07B7.72$493.70M$7.4844.93

In the previous week, Align Technology had 1 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 5 mentions for Align Technology and 4 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 0.97 beat Align Technology's score of 0.48 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Align Technology
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
West Pharmaceutical Services
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

West Pharmaceutical Services has a net margin of 16.85% compared to Align Technology's net margin of 10.50%. West Pharmaceutical Services' return on equity of 19.03% beat Align Technology's return on equity.

Company Net Margins Return on Equity Return on Assets
Align Technology10.50% 15.82% 10.17%
West Pharmaceutical Services 16.85%19.03%14.06%

Align Technology has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

88.4% of Align Technology shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.8% of Align Technology shares are owned by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

West Pharmaceutical Services beats Align Technology on 12 of the 17 factors compared between the two stocks.

How does West Pharmaceutical Services compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Merit Medical Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Merit Medical Systems currently has a consensus price target of $92.80, indicating a potential upside of 37.95%. West Pharmaceutical Services has a consensus price target of $340.09, indicating a potential upside of 1.19%. Given Merit Medical Systems' higher possible upside, equities analysts plainly believe Merit Medical Systems is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Merit Medical Systems
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.64
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00

99.7% of Merit Medical Systems shares are held by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.7% of Merit Medical Systems shares are held by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Merit Medical Systems and Merit Medical Systems both had 4 articles in the media. Merit Medical Systems' average media sentiment score of 1.25 beat West Pharmaceutical Services' score of 0.97 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Merit Medical Systems
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
West Pharmaceutical Services
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

West Pharmaceutical Services has higher revenue and earnings than Merit Medical Systems. Merit Medical Systems is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$1.54B2.60$128.49M$2.3129.12
West Pharmaceutical Services$3.07B7.72$493.70M$7.4844.93

West Pharmaceutical Services has a net margin of 16.85% compared to Merit Medical Systems' net margin of 9.03%. West Pharmaceutical Services' return on equity of 19.03% beat Merit Medical Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Merit Medical Systems9.03% 13.54% 7.94%
West Pharmaceutical Services 16.85%19.03%14.06%

Summary

West Pharmaceutical Services beats Merit Medical Systems on 12 of the 16 factors compared between the two stocks.

Get West Pharmaceutical Services News Delivered to You Automatically

Sign up to receive the latest news and ratings for WST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

WST vs. The Competition

MetricWest Pharmaceutical ServicesMED/DENTAL IndustryMedical SectorNYSE Exchange
Market Cap$23.74B$15.00B$6.47B$23.13B
Dividend Yield0.27%1.35%2.68%4.06%
P/E Ratio44.9318.1124.7131.08
Price / Sales7.722.16519.5520.72
Price / Cash33.6813.7627.9218.65
Price / Book7.623.2410.824.65
Net Income$493.70M$534.24M$3.56B$1.07B
7 Day Performance1.92%-0.93%1.68%-1.05%
1 Month Performance6.07%1.63%0.44%0.18%
1 Year Performance54.84%1.37%32.84%24.24%

West Pharmaceutical Services Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WST
West Pharmaceutical Services
3.2743 of 5 stars
$336.09
+1.9%
$340.09
+1.2%
+52.5%$23.74B$3.07B44.9310,800
CHE
Chemed
4.3768 of 5 stars
$423.37
+1.0%
$501.50
+18.5%
-20.2%$5.57B$2.53B23.0715,811
EHC
Encompass Health
4.7624 of 5 stars
$99.13
-2.3%
$143.86
+45.1%
-17.2%$10.07B$5.94B16.5542,000
COO
Cooper Companies
3.7831 of 5 stars
$67.76
-0.2%
$82.64
+22.0%
-5.8%$13.24B$4.09B57.4215,000
ALGN
Align Technology
4.1493 of 5 stars
$178.26
+2.0%
$205.85
+15.5%
-4.4%$12.52B$4.03B29.9120,290

Related Companies and Tools


This page (NYSE:WST) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners